Algert Global’s Vir Biotechnology VIR Stock Holding History

Algert Global’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.2M	Buy	804,977 +315,969	+65%	+$3.01M	0.1%	344
2026 Q1	$4.38M	Buy	+489,008	New	+$3.9M	0.07%	477
2025 Q3	–	Sell	-19,802	Closed	-$99.8K	–	1355
2025 Q2	$99.8K	Hold	19,802	–	–	﹤0.01%	1140
2025 Q1	$128K	Hold	19,802	–	–	﹤0.01%	1116
2024 Q4	$145K	Sell	19,802 -193,663	-91%	-$1.53M	﹤0.01%	1097
2024 Q3	$1.6M	Buy	213,465 +46,630	+28%	+$405K	0.04%	631
2024 Q2	$1.48M	Buy	+166,835	New	+$1.6M	0.05%	560
2024 Q1	–	Sell	-31,960	Closed	-$322K	–	1284
2023 Q4	$322K	Sell	31,960 -417,725	-93%	-$3.82M	0.01%	923
2023 Q3	$4.21M	Buy	+449,685	New	+$6.41M	0.2%	156
2023 Q1	–	Sell	-16,510	Closed	-$418K	–	1322
2022 Q4	$418K	Buy	+16,510	New	+$405K	0.02%	862
2022 Q2	–	Sell	-19,465	Closed	-$501K	–	1397
2022 Q1	$501K	Buy	19,465 +12,346	+173%	+$366K	0.03%	813
2021 Q4	$298K	Sell	7,119 -1,050	-13%	-$41.1K	0.04%	732
2021 Q3	$356K	Buy	+8,169	New	+$354K	0.05%	686

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Algert Global's VIR Position: Q2 2026 in Review

Algert Global increased its Vir Biotechnology (VIR) stake by 65% in Q2 2026, buying an estimated $3.01M and bringing the position to 804,977 shares worth $8.2M. The position accounts for 0.1% of the portfolio, ranked #344.

Algert Global first reported a position in VIR in Q3 2021 and has held it in 13 quarters since. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Algert Global held 804,977 shares of Vir Biotechnology worth $8.2M as of Q2 2026.
Algert Global bought 315,969 Vir Biotechnology shares in Q2 2026, an estimated $3.01M.
Vir Biotechnology made up 0.1% of Algert Global's portfolio in Q2 2026, its #344 holding.
Algert Global first reported a position in Vir Biotechnology in Q3 2021 and has held it in 13 quarters since.
238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.